Melanotan II FAQ: common questions answered
An unapproved tanning peptide with small human trials and reports of serious harm.
Also called: Melanotan-2, MT-II, MT2, MT-2.
Melanocortin agonists · Nonselective melanocortin receptor agonist.
- Is Melanotan II FDA-approved? No. FDA documented a 2007 warning over illegal MT-II sales. PCAC review is planned before February 2027; no approval or favorable decision was found.
- How do people take it? Under the skin, daily for 2 weeks, then three times weekly. Source: reported by users, not an established dose.
- What's the difference between Melanotan II and Bremelanotide? Melanotan II: an unapproved tanning peptide with small human trials and reports of serious harm. Bremelanotide: an as-needed injection for low libido before menopause; nausea is common. Why people pair them: a community poster combined tanning use with a libido schedule.
- Can I take it with Bremelanotide? A community poster combined tanning use with a libido schedule. Duplicate melanocortin activity; no combination trial. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Inferred under S0: no human therapeutic approval was found. Melanotan II is not named as an example in the list.
- How long does a mixed vial last? Users report refrigeration. No validated sterile shelf life after mixing was found.
Related to Melanotan II
- Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
- Melanotan I / Afamelanotide: The molecule in an approved EPP implant; online tanning powder is a different formulation.
- Setmelanotide: A daily injection approved for specific genetic obesity and acquired hypothalamic obesity.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, US Food and Drug Administration · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2026
- Melanotan II tanning peptide products found to be inconsistently dosed, 2026
- Scenesse, 2026
- Scenesse, INN-afamelanotide, 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Don’t risk using tanning products containing melanotan, 2025
- Written questions and answers - Written questions, answers and statements - UK Parliament, 2025
- Priapism (painful erections) - NHS, NHS · 2023
- Notice of Opportunity for Hearing (NOOH) Manookian, Edward 8/5/16, 2016
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.